Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2003-01-22 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Clairification re Term of the GTG Non-Coding Patents 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Australian Stock Exchange Company Announcements Office, clarifying the term of certain patents held by Genetic Technologies Limited. It discusses the expiry dates of patents and their implications for licensing. The document is short (2390 characters) and serves as a market clarification or update rather than a financial report or regulatory filing. It does not contain financial statements, management changes, voting results, or legal proceedings. It is an announcement providing information to the market about intellectual property assets. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2003-01-22 English
App 3B-Quotation of ord shrs re:release of escrow conditions 11 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the new issue of securities, application for quotation of additional securities, and agreement. It includes detailed information about the class of securities issued, number of securities, issue price, purpose of the issue, and dates related to the securities. The document references ASX (Australian Securities Exchange) rules and is a formal notification of a capital raising event or share issue. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about a capital/financing activity, specifically a new share issue and quotation application. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a brief notice or report publication announcement.
2002-12-30 English
Change of Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director's Interest Notice' under ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities holdings of a director, including the number of shares acquired, disposed, and held before and after the change. This is a report of personal share transactions by a company director. It does not contain financial results, management discussion, or other report types. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is a full notice, not just an announcement or certification.
2002-12-18 English
Publication of the Mouse Genome/Significance to GTG 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a letter dated 12 December 2002 addressed to the Australian Stock Exchange Limited. It discusses the publication of the mouse genome and its significance to Genetic Technologies Limited (GTG), focusing on the scientific and strategic importance of non-coding DNA patents and licensing programs. The content is informative and promotional about the company's intellectual property and recent scientific developments, but it does not contain financial statements, earnings data, or regulatory filings. It is not a report, audit, or financial update, nor does it announce voting results, management changes, or capital activities. The document is a market announcement providing detailed information about a scientific development relevant to the company and its business. Given the nature of the content and the addressee (Company Announcements Office), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2002-12-11 English
Bringing the latest advances in Cancer SusceptibilityTesting 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a letter dated 9 December 2002 from the Executive Chairman of Genetic Technologies Limited to the Australian Stock Exchange. It discusses the company's strategic alliance with Myriad Genetics to bring cancer susceptibility testing to Australia and clarifies the company's position on research support, testing comprehensiveness, costs, and access. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a market announcement clarifying business strategy and partnership developments rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is a general regulatory announcement to the stock exchange about company activities and clarifications, which fits best under Regulatory Filings (RNS). The document length is moderate and contains substantive content but is not a formal report or presentation. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2002-12-08 English
Forthcoming release of restricted securities 1 page
Director's Dealing Classification · 95% confidence The document is a letter addressed to the Australian Stock Exchange announcing the forthcoming release of restricted securities owned by Dr. Mervyn Jacobson and associated interests. It discusses the release of shares from escrow and intentions regarding selling shares. This is a notification related to shareholding and insider transactions rather than a financial report, earnings release, or management discussion. The mention of previously reported Appendix 3Y (which relates to insider trading disclosures) supports this. Therefore, the document fits best under Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2002-12-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.